March 24, 2015Open Access

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Tewari et al. (Tue,) studied this question.

synapsesocial.com/papers/69dc99d789c4deb67d359366 https://doi.org/https://doi.org/10.1200/jco.2014.55.9898

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?2008 · 11 citations
2Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer2006 · 2,625 citations
3Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study2007 · 3 citations
4Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.1995 · 196 citations
5Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.1983 · 197 citations

Me gusta

Guardar

Ver artículo completo